^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Oncophage (Heat Shock Protein Peptide Complex-96)

i
Other names: Heat Shock Protein Peptide Complex-96, G-100, HSPPC-96, NP-150, Prophage series, G-200, gp96 heat shock protein-peptide complex vaccine
Associations
Company:
Agenus
Drug class:
Tumor-associated antigen inhibitor
Associations
4ms
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) (clinicaltrials.gov)
P2, N=90, Terminated, National Cancer Institute (NCI) | Completed --> Terminated; Study closed early due to poor accrual.
Trial termination • Surgery
|
PD-L1 (Programmed death ligand 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
Keytruda (pembrolizumab) • temozolomide • Oncophage (Heat Shock Protein Peptide Complex-96)
over1year
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery (clinicaltrials.gov)
P2, N=90, Terminated, Alliance for Clinical Trials in Oncology | Active, not recruiting --> Terminated; DSMB futility analysis
Trial termination
|
Avastin (bevacizumab) • Oncophage (Heat Shock Protein Peptide Complex-96)
almost2years
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) (clinicaltrials.gov)
P2, N=90, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Dec 2022
Trial completion • Trial completion date • Surgery
|
PD-L1 (Programmed death ligand 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
IDH wild-type
|
Keytruda (pembrolizumab) • temozolomide • Oncophage (Heat Shock Protein Peptide Complex-96)
3years
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) (clinicaltrials.gov)
P2, N=74, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | N=310 --> 74
Clinical • Enrollment closed • Enrollment change
|
PD-L1 (Programmed death ligand 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
Keytruda (pembrolizumab) • temozolomide • Oncophage (Heat Shock Protein Peptide Complex-96)
over3years
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) (clinicaltrials.gov)
P2, N=310, Recruiting, National Cancer Institute (NCI) | N=108 --> 310 | Trial completion date: Jun 2024 --> Jan 2025 | Trial primary completion date: Mar 2022 --> Jan 2023
Clinical • Enrollment change • Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
Keytruda (pembrolizumab) • temozolomide • Oncophage (Heat Shock Protein Peptide Complex-96)
almost4years
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) (clinicaltrials.gov)
P2, N=108, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2024 --> Jun 2024 | Trial primary completion date: Jan 2021 --> Mar 2022
Clinical • Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
Keytruda (pembrolizumab) • temozolomide • Oncophage (Heat Shock Protein Peptide Complex-96)
over4years
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) (clinicaltrials.gov)
P2, N=108, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting | N=14 --> 108
Clinical • Enrollment open • Enrollment change
|
PD-L1 (Programmed death ligand 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
Keytruda (pembrolizumab) • temozolomide • Oncophage (Heat Shock Protein Peptide Complex-96)